Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Personalis Inc (PSNL)

Personalis Inc (PSNL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 848,966
  • Shares Outstanding, K 88,804
  • Annual Sales, $ 84,610 K
  • Annual Income, $ -81,280 K
  • EBIT $ -81 M
  • EBITDA $ -73 M
  • 60-Month Beta 1.99
  • Price/Sales 11.00
  • Price/Cash Flow N/A
  • Price/Book 5.43

Options Overview Details

View History
  • Implied Volatility 210.76% (+5.43%)
  • Historical Volatility 113.78%
  • IV Percentile 72%
  • IV Rank 24.04%
  • IV High 556.11% on 04/15/25
  • IV Low 101.48% on 12/02/25
  • Expected Move (DTE 10) 1.47 (14.97%)
  • Put/Call Vol Ratio 0.27
  • Today's Volume 71
  • Volume Avg (30-Day) 175
  • Put/Call OI Ratio 0.54
  • Today's Open Interest 4,128
  • Open Int (30-Day) 3,995
  • Expected Range 8.35 to 11.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.31
  • Number of Estimates 1
  • High Estimate -0.31
  • Low Estimate -0.31
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -34.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.11 +38.12%
on 11/18/25
11.40 -13.86%
on 11/26/25
+2.89 (+41.70%)
since 11/07/25
3-Month
5.26 +86.87%
on 09/09/25
11.40 -13.86%
on 11/26/25
+4.50 (+84.59%)
since 09/08/25
52-Week
2.83 +247.00%
on 04/07/25
11.40 -13.86%
on 11/26/25
+5.67 (+136.63%)
since 12/06/24

Most Recent Stories

More News
Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the Piper Sandler 37 th Annual Healthcare...

PSNL : 9.82 (+2.72%)
Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage of its ultrasensitive NeXT Personal® test for surveillance of cancer recurrence...

PSNL : 9.82 (+2.72%)
Personalis: Q3 Earnings Snapshot

Personalis: Q3 Earnings Snapshot

PSNL : 9.82 (+2.72%)
Personalis Reports Third Quarter 2025 Financial Results

Company Advances "Win-in-MRD" Strategy with Compelling Clinical Trial Data and Increasing Physician Adoption of NeXT Personal® Platform

PSNL : 9.82 (+2.72%)
Personalis to Announce Third Quarter 2025 Financial Results

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025. In conjunction...

PSNL : 9.82 (+2.72%)
Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (LAURA). The findings demonstrate that...

PSNL : 9.82 (+2.72%)
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on September 15, 2025,...

PSNL : 9.82 (+2.72%)
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced its collaboration with a leading breast cancer team from Yale Cancer Center for a clinical trial titled...

PSNL : 9.82 (+2.72%)
Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (NeoADAURA). The findings demonstrate...

PSNL : 9.82 (+2.72%)
Personalis to Participate in Upcoming Investor Conferences

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the following conferences: ...

PSNL : 9.82 (+2.72%)

Business Summary

Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.

See More

Key Turning Points

3rd Resistance Point 10.36
2nd Resistance Point 10.10
1st Resistance Point 9.96
Last Price 9.82
1st Support Level 9.55
2nd Support Level 9.29
3rd Support Level 9.15

See More

52-Week High 11.40
Last Price 9.82
Fibonacci 61.8% 8.13
Fibonacci 50% 7.11
Fibonacci 38.2% 6.10
52-Week Low 2.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar